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Abstract Background: Kawasaki disease is an acute systemic vasculitis. Cardiac complications are frequent and
include endothelial dysfunction in patients with coronary anomalies. Thus far, endothelial dysfunction in
patients with no coronary lesions is poorly understood. Our aim was to access the vascular function in adolescents
and young adults long term after Kawasaki disease, but without coronary aneurysms or any other cardiac risk
factors. Methods: We carried out a single-centre prospective study in a Portuguese population. We evaluated two
groups of subjects: (1) Kawasaki disease patients over 11 years of age, diagnosed >5 years ago, with no coronary
lesions or any other risk factors for cardiovascular disease; (2) control group of individuals without cardiovascular
risk factors. Patients and controls were clinically assessed. Endo-PAT and carotid intima-media thickness
assessment were performed to determine vascular function. Results: In total, 43 Kawasaki disease patients were
assessed and compared with 43 controls. Kawasaki disease patients presented a decreased reactive hyperaemia
index compared with controls (1.59± 0.45 versus 1.98± 0.41; p< 0.001). Augmentation index was similar in
both groups (−4.5± 7 versus −5± 9%; p 0.6). The mean carotid intima-media thickness was not signiﬁcantly
increased in the Kawasaki disease group. There were no statistically signiﬁcant changes with regard to
laboratory data. Conclusions: Children with Kawasaki disease may have long-term sequelae, even when there is no
discernible coronary artery involvement in the acute stage of the disease. Further research is needed to assess whether
known strategies to improve endothelial function would bring potential beneﬁts to Kawasaki disease patients.
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KAWASAKI DISEASE IS AN ACUTE SYSTEMIC VASCULITISof medium- and small-sized arteries thatoccurs predominantly in children under
5 years of age. It is now known to occur worldwide
in children of all ethnicities, with different incidence
rates.1 In Portugal, the incidence rate was 6.5 per
100,000 children aged 0–4 years in 2000–2011.2
A multifactorial aetiology is accepted, where
an infectious trigger, in a favourable ambient
environment, can act on genetically susceptible
individuals causing Kawasaki disease.3–5 It is
typically self-limited, and its major complication is
the occurrence of coronary artery aneurysms, which
can develop in nearly 25% of untreated patients and
5–10% of treated patients. Hence, the treatment in
the acute phase is focussed on preventing coronary
ectasias and potential thrombotic occlusions.6
A good prognosis is generally expected for patients
with Kawasaki disease, and no cardiac involvement or
only mild and transient dilatation of the coronary
arteries, without aneurysm formation, are observed
in those who recover without sequelae. Although
some studies performed in children and adolescents
have hypothesised that previous Kawasaki disease
is a potential risk factor for early onset of
atherosclerosis,7–12 others have shown that the
vascular changes represent a speciﬁc form of
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vasculopathy. Burns et al reported their ﬁndings on
autopsy studies of adults who died of complications
related to undiagnosed Kawasaki disease in childhood.
No classical histological changes in atherosclerosis
were found. Instead, long-term histopathological
abnormalities such as subacute and chronic vasculitis
or luminal myoﬁbroblastic proliferation were
observed, causing increased thickness of the arterial
wall and decreased lumen of the coronary arteries with
replacement of normal endothelium in the affected
areas, by dysfunctional endothelial cells, perpetuating
the inﬂammatory process, expressed as abnormal
inﬂammatory parameters.9,10,13,14
Patients with coronary artery aneurysms and those
with regressed aneurysms may also have endothelial
dysfunction and increased intima-media thickness of
the carotid arteries.11–19 There is conﬂicting evidence
that an abnormal endothelial function can also be
shown in patients without coronary involvement, long
term after the Kawasaki disease episode.8,10,11,15,18–22
Understanding vascular function long term after
Kawasaki disease can enlighten our knowledge of this
pathological process and the need for changes in the
long-term follow-up of these patients.
Endothelial function can be assessed using reactive
hyperaemia in the peripheral arteries, a physiological
response based on dilatation of the target artery in
response to increased blood ﬂow after shear stress.23–25
Endothelial peripheral arterial tonometry (EndoPat) is a
technique that measures changes in digital pulse
volume, assessed at the ﬁnger tips, before and after
reactive hyperaemia.26–29 The augmentation index, a
measure of arterial stiffness, is also obtained during
EndoPat examination, and several studies have
demonstrated its association with cardiovascular risk
factors,30,31 although it is still an exploratory method.
Carotid intima-media thickness has been used as
a non-invasive method to test early or subclinical ather-
osclerotic changes, both in children and adults.32 It has
also been used as a surrogate marker for both coronary
and peripheral artery atherosclerosis. Several studies were
performed to studied carotid intima-media thickness
changes in children with Kawasaki disease, showing
conﬂicting results.7,18,19,33,34
The aim of this study was to access vascular function
in adolescents and young adults long term after Kawa-
saki disease, but without coronary aneurysms or any
other cardiac risk factors; the present study was a single-
centre, prospective study in a Portuguese population.
Materials and methods
Overall
This present study was a single-institution,
prospective study, and the investigators were blinded
to the study protocol. The study was approved by the
Institutional Ethics Committee, and an informed
consent was obtained from all subjects or their parents.
Clinical evaluation, questionnaire administration,
electrocardiography, and echocardiography were
performed by the same investigator – a senior
paediatric cardiologist. EndoPat and assessment of
carotid artery intima-media thickness were per-
formed always by the same senior operators, with
extensive experience, for each technique, and they
were unaware of patient or control status.
Study subjects
This study included 43 adolescents and young adults
with previous history of Kawasaki disease without
coronary aneurysms, followed-up at our centre. The
Kawasaki disease group included patients diagnosed
with the disease at least 5 years earlier (mean± SD:
15.8± 6.8 years) and aged more than 12 years
(mean± SD: 19.1± 6.8 years); 43 age- and sex-
matched healthy controls (mean± SD: 18.9± 5.4
years) with no previous history of cardiac disease
comprised the control group.
All the study participants were Portuguese,
caucasians, non-smokers, deﬁned as individuals who
had never smoked, were not born prematurely, and
had no medical history of hypertension, hypergly-
caemia, hypercholesterolaemia, or obesity, deﬁned as
body mass index >30 for adults or BMI >30 kg/m2
for adolescents under 20 years of age – ⩾ 95th
percentile.35 In addition, they did not have a family
history of hereditary diseases such as homocystinuria
or familial hypercholesterolaemia.
All subjects in the Kawasaki group had the diag-
nosis of Kawasaki disease made in conformity with
international guidelines,36 and cardiovascular exam-
ination was performed by a paediatric cardiologist.
The presence of coronary aneurysms was excluded in
all patients; they were all discontinued from follow-
up, at least 1 year after Kawasaki disease diagnosis,
without symptoms or any cardiovascular sequelae.
The control group included healthy volunteers and
normal subjects referred to the paediatric cardiology
outpatient clinic because of asymptomatic heart
murmur, chest pain, or other ill-deﬁned symptoms,
whose investigation excluded cardiac disease; all of
them willingly took part in this study.
Investigation was deferred for at least 4 weeks in
subjects with acute illnesses such as febrile illness or
viral syndromes.
Study protocol
All subjects were advised against consuming food and
drinks, except for water, overnight or for at least
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12 hours, and against performing heavy exercise
and consuming caffeine on the day before the
examination.
We obtained the past history for Kawasaki disease
in all subjects; we measured weight, height, and
blood pressure automatically on the dominant arm in
the sitting position using the oscillometric method
after at least 15 minutes of resting. In total, three
blood pressure measurements were obtained and the
mean value was used. All subjects were coded before
performing other techniques, so that the investigators
would remain blinded to their condition.
Endothelial function was then assessed using
Endo-PAT2000 (Itamar Medical Ltd, Cesarea, Israel)
in a quiet examination room at 23–25°C before blood
sampling for analysis. Venous blood samples were
subsequently collected. EndoPat was repeated
3–4 weeks latter to assess reproducibility of this test.
After having breakfast, all subjects underwent
echocardiography, electrocardiogram, and bilateral
carotid ultrasound examination.
Assessment of endothelial function
The Endothelial Pulse Amplitude Test (EndoPAT) is
a CE (Conformité Européenne) mark-approved device
that analyses reactive hyperaemia after compression of
the non-dominant arm. This technique has been
validated in adults and in different paediatric groups.
The cut-off value of 1.67 indicates dysfunction for
lower values. It has been demonstrated that lower
Endo-PAT index is associated with increased cardio-
vascular risk.37–40
The participants rested in the supine position with
both hands at the same level. Speciﬁc ﬁnger probes
for recording pulse amplitude volume curves were
placed on the index ﬁnger of each hand, and a blood
pressure cuff was placed on the non-dominant upper
arm (study arm), whereas the other arm served as a the
control (control arm). After continuous recording of
the pulse amplitude volume curves signal from both
hands for 10 minutes, the blood pressure cuff on the
study arm was inﬂated to whichever pressure would
be higher, 200 or 60mmHg plus systolic blood
pressure, for 5 minutes. The blood pressure cuff was
then rapidly deﬂated to induce hyperaemia in the
study arm while the pulse amplitude volume curves
signal continued to be recorded for 10 minutes. Data
were analysed automatically by the software of the
device. In brief, the reactive hyperaemia index was
calculated as the ratio of the average amplitude of
pulse amplitude volume curves signal over 1-minute
time interval, starting 90 seconds after cuff deﬂation,
over the average amplitude of the PAT signal of the
210-second period before cuff inﬂation (baseline),
which was then multiplied by a baseline correction
software factor. Reactive hyperaemia index values from
the study arm were then normalised to the control arm,
in order to compensate for potential systemic changes.
A reactive hyperaemia index value ⩽1.67 was used as
the cut-off to diagnose endothelial dysfunction. We
have demonstrated previously the feasibility, safety,
and reproducibility of this test in adolescents with
Kawasaki disease and normal controls.40
Assessment of arterial stiffness
Arterial stiffness was measured using the augmentation
index obtained during EndoPat examination.
Augmentation index is deﬁned as an increment in
pressure after the ﬁrst systolic shoulder to the peak of
aortic pressure and is expressed as a percentage of aortic
pulse pressure. Pressure sensors within this particular
ﬁnger probe capture the beat-by-beat ﬁnger pulse wave
amplitude, which is then ﬁltered, ampliﬁed, and
graphically displayed on a computer screen. A com-
puterised algorithm was generated to automatically
identify peak pressures and the inﬂection point. The
augmentation index is calculated by averaging the
pulse wave amplitude data over a period of 210
seconds, and is deﬁned as the difference between the
second and the ﬁrst systolic peaks expressed as
a percentage of the pulse pressure. The augmentation
index adjusted to 75 beats/minute was calculated by
adjusting the augmentation index to a 75 beats/minute
variable, as this measurement is inﬂuenced by heart
rate. Both variables are still considered exploratory, and
the results are analysed according to this view.
Blood sampling and analysis
Fasting total cholesterol, HDL cholesterol, LDL
cholesterol and triglyceride levels as well as glucose
and C-reactive protein levels were collected on the
day of the visit after the vascular tests were
completed.
Carotid ultrasound
Carotid ultrasound examination of both carotid
arteries was performed to assess the thickness of the
intima-media portion of the carotid artery as a marker
of structural changes of the arterial wall. An increased
carotid arterial intima-media thickness has been
reported as a surrogate marker of early-onset
atherosclerosis.4
The study was performed with a high-resolution,
B-mode system equipped with a high-frequency,
linear-phased array transducer (Acusson Sequoia
echocardiography system C512, probe: 15MHz–15
L8; Siemens). Measurements were performed by two
senior operators, blinded to subjects diagnosis.
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Subjects were allowed to rest in the supine
position with slight contralateral hyperextension
and lateral rotation of the neck. A clear three-lead
electrocardiographic signal was simultaneously
obtained. The probe was positioned laterally to
obtain the best resolution image of the lumen–intima
interface. Common carotid bifurcation and the
proximal segment of the artery until the carotid sinus
were identiﬁed in a longitudinal B-mode plane. The
carotid arterial intima-media thickness measure-
ments were obtained at the far wall of the common
carotid at least in 1 cm segment at the distal end
of the common carotid artery, according to the
recommendations of the American Society of
Echocardiography.41,42
The right common carotid artery and the left
common carotid artery were examined, and the
frames were digitally recorded. Measurements were
performed ofﬂine with a semi-automatic software
(SingoDynamics, Siemens, Munich, Germany); they
included carotid arterial intima-media thickness
means, maximums, and standard deviation. When-
ever necessary, the automatic detected contour of the
arterial wall was corrected manually. We also eval-
uated the presence of atherosclerotic plaques, deﬁned
as a focal thickness of ⩾ 50% of the adjacent wall or
⩾1.5mm, or abnormalities of ﬂow.
Statistical analysis
Patient characteristics including lipid proﬁle and
vascular variables were compared with the control
group. Primary end points were EndoPat indices and
carotid arterial intima-media thickness. Data were
analysed using SPSS 20.0 software (SPSS, Chicago,
Illinois, Unites States of America). Discrete variables
are presented as frequency (percentage) or means±
standard deviation. The normal distribution of
variables was examined using the Shapiro–Wilk’s
test. To compare them, between the Kawasaki disease
group and the control group, Student’s t-test
was used when normality was conﬁrmed or the
Mann–Whitney test when they did not follow a
normal distribution. The analysis of categorical vari-
ables was performed using the χ2-test. If the expected
frequency was lower than 5, Fisher’s exact test was
utilised. A multivariate regression analysis was used
to determine the relationship between reactive
hyperaemia index and carotid arterial intima-media
thickness, indicative of disease and the different
factors including the variables that were found
to be statistically signiﬁcant in the bivariate
analysis or the clinical impact of which had been
veriﬁed in previous studies, such as age, weight,
body mass index, lipid proﬁle, and elevated
C-reactive protein. A p value of<0.05 was considered
statistically signiﬁcant, for a conﬁdence interval of




Kawasaki disease and control group patients did not
differ signiﬁcantly with regard to gender, age,
weight, height, body mass index, and blood pressure.
Both groups also had similar medical history,
cardiovascular risk factors, and laboratory proﬁle,
including lipids, proteins, and C-reactive protein
levels (Table 1), with no statistical signiﬁcance in the
univariate or multivariate analysis. There was a trend
towards increased lipid proﬁle levels in the Kawasaki
disease group, with higher triglycerides (73.93mg/dl
[with a range from 143 to 24mg/dl] versus
74.48mg/dl [with a range from 140 to 32mg/dl],
p 0.73), total cholesterol (159.38mg/dl [with a range
from 187 to 111mg/dl] versus 152.12mg/dl [with
a range from 178 to 110mg/dl], p 0.14), HDL
cholesterol (54.93mg/dl [with a range from 74 to
36mg/dl] versus 49.93mg/dl [with a range from 69
to 30mg/dl], p 0.04), and LDL cholesterol
(96.93mg/dl [with a range from 126 to 52mg/dl]
versus 93.61mg/dl [with a range from 126 to 58
mg/dl], p 0.43). The only value with weak statistical
signiﬁcance was HDL cholesterol (p= 0.04).
All subjects had normal electrocardiograms and
echocardiographic evaluation.
Kawasaki disease history
Patients in the Kawasaki disease group had the
disease at 3.90± 2.03 years of age (with a range from
7.4 to 0.4 years). The elapsed time between the acute
episode and the present study was 15.8± 6.8 years
(with a range from 28 to 6 years), free of disease, and
there were no relapses.
The vast majority of the patients had typical
Kawasaki disease (95%), only two patients had the
atypical form, all patients had the diagnosis accord-
ing to established diagnostic criteria, and all had
cardiovascular screening on the 1st day of diagnosis
and on follow-up. On cardiac evaluation, 35 patients
had normal coronary arteries and eight children
(18.6%) had transient dilatation (Z-score <3), which
returned to normal in about 1 month. Intravenous
immunoglobulin was administered to 38 patients
(88.4%) at an average of 7 days (with a range from 2
to 15 days) from fever onset. All patients were
medicated with aspirin for 6 months, and cardiac
follow-up was maintained for an average of
11 months (with a range from 8 to 21 months).
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Endothelial function
The Endothelial Pulse Amplitude Test (EndoPAT) was
performed and repeated; the results demonstrated their
reproducibility without statistically signiﬁcant differ-
ences between them in both groups: Kawasaki disease
patients had a mean reactive hyperaemia index of
1.59± 0.45 and 1.62± 0.41 (ﬁrst and second assess-
ment, respectively), whereas control group had mean
values of 1.98± 0.41 and 2.01± 0.43, (Table 2). There
was a good correlation between both studies (Pearson’s
correlation 0.958, p value <0.001).
Endothelial dysfunction was found in the majority
(n=34; 79.06%) of Kawasaki disease patients, when
compared with a signiﬁcantly lower percentage of con-
trol subjects (n=8; 18.60%). There were signiﬁcant
group differences in pulse wave amplitude-derived
reactive hyperaemia index, with Kawasaki disease
patients having a signiﬁcantly lower reactive hyper-
aemia index when compared with the control group
(1.59 and 1.62 versus 1.98 and 2.01; p<0.001) (Fig 1).
Pulse wave amplitude-derived augmentation
index in both measurements were within the normal
range and similar for both groups (−4.5± 7 and
−4± 8 versus −5± 9 and −4.5± 9% p 0.61 and
p 0.63 for Kawasaki and controls group, respectively)
with no statistical signiﬁcance; the same results were
obtained for the augmentation index adjusted to 75
beats/minute (Table 2).
Carotid intima-media thickness
The maximum carotid arterial intima-media thickness
results were slightly higher for the Kawasaki disease
patients, but without signiﬁcance (left common carotid
artery maximum: 0.587±0.100 versus 0.575±0.065;
p 0.22; right common carotid artery maximum:
0.598±0.082 versus 0.574±0.074; p 0.34), whereas
the carotid arterial intima-media thickness mean values
were similar for both groups, (left common carotid artery
mean: 0.447±0.088 versus 0.443±0.059; p 0.93;
right common carotid artery mean: 0.441±0.073 ver-
sus 0.438±0.058; p 0.89) (Table 3). There were some
outliers for these values in both groups; nevertheless,
when we excluded the outliers, there was no change in
the signiﬁcance. We also found that 97.7 and 95.3% of
subjects in the Kawasaki and control group, respectively,
had mean carotid arterial intima-media thickness values
under 6mm. No plaques or ﬂow abnormalities were
identiﬁed in either group by carotid ultrasound imaging
(Figs 2 and 3). In the multivariate analysis, the main
factor associated with Kawasaki disease was an abnormal
reactive hyperaemia index (odds ratio=16.5; 95%
conﬁdence interval, 5.7-47.8; p<0.001) (Table 4).
Discussion
Kawasaki disease occurs worldwide as both endemic
and community-based epidemic forms in children of
Table 1. Descriptive variables.
Kawasaki group (n= 43) Control group (n= 43) p Value
Demographics
Age at test (years) 19.09± 6.78 18.86± 5.35 0.79*
Male sex (%) 62.8 62.8 1**
Height (cm) 156.92± 13.46 167.46± 13.47 0.15*
Weight (kg) 48.40± 11.01 59.32± 14.67 0.12*
BMI (kg/m2) (adults) 20.89± 2.04 21.12± 2.42 0.50*
Percentile BMI (children) 44.80± 22.45 44.36± 24.38 0.80*
Blood pressure (mmHg)
Systolic 111.77± 10.47 112.21± 9.40 0.84**
Diastolic 66.69± 8.87 65.07± 7.01 0.35**
Laboratory analysis
Triglycerides 73.93± 24.64 70.48± 22.88 0.73**
Total cholesterol (mg/dl) 159.38± 25.35 152.12± 22.07 0.14*
HDL (mg/dl) 54.93± 11.48 49.93± 10.23 0.04**
LDL (mg/dl) 96.93± 20.63 93.61± 18.48 0.43*
CRP (mg/dl) 1.11± 1.08 1.01± 1.12 0.14*
Total proteins (mg/dl) 73.38± 4.58 72.95± 3.89 0.33*
Albumin (mg/dl) 43.52± 3.49 43.85± 3.32 0.65**
Glucose (mg/dl) 81.79± 7.91 80.72± 8.98 0.56**
Elapsed time after Kawasaki disease
Years (until test) 15.8± 6.8 – –
BMI= body mass index; CRP=C-reactive protein
Values are means± standard deviation
*Mann–Whitney U-test
**Student’s t-test
Pinto et al: Vascular function long term after Kawasaki disease 5
all races. It is a medium-vessel vasculitis with
predominant involvement of the coronary arteries. The
search for an aetiological agent has been wide ranging.
Kawasaki disease is accompanied by signiﬁcant
derangements in the immunoregulatory system3–5 that
lead to coronary inﬂammation and disruption with
dilatation and aneurysm formation. Endothelial cell
damage appears to occur as a result of this increased
immune activity.
The long-term prognosis of Kawasaki disease, par-
ticularly in patients with normal coronary arteries,
mild dilatation, or regressed coronary aneurysms,
remains uncertain at present. Several authors have
demonstrated that 50% of aneurysms regress within
several years with a normal angiographic lumen;6,10
however, histological studies and intra-coronary ultra-
sound examinations have demonstrated persistent
abnormal arterial walls with marked thickening of
intima, which may be caused by the proliferation
of smooth muscle cells.12,15
Besides these morphological abnormalities, it has
also been demonstrated that Kawasaki disease has a
deleterious effect on coronary artery function, years
after the acute presentation, particularly in patients
with persistent coronary artery aneurysms when
compared with control subjects.6,12,14,15 Abnormal
coronary ﬂow reserve has been demonstrated in
Kawasaki disease patients with transiently dilated
coronary arteries17 and in those without antecedent
coronary artery dilation or ischaemia.43,44
Abnormalities in endothelial function,10,11,15,18,19,40
arterial stiffness,45–47 and carotid intima-media thick-
ness have also been observed.33,34,48 Nevertheless,
controversy persists, and other studies have failed to
Figure 1.
Box plots of reactive hyperaemia index (RHI) testing in Kawasaki disease patients and controls using Mann–Whitney U-test. The red line
represents the cut-off value of 1.67 for RHI (normal endothelial function RHI> 1.67).
Table 2. EndoPat results.
Kawasaki group (n= 43) Control group (n= 43) p Value
RHI (1) 1.59± 0.45 1.98± 0.45 <0.001*
RHI (2) 1.62± 0.41 2.01± 0.43 <0.001*
RHI mean (1_2) 1.60± 0.42 1.99± 0.43 <0.001*
AIx (1) (%) −4.5± 7 −5± 9 0.61**
AIx (2) (%) −4± 8 −4.5± 9 0.63**
AIx mean (1_2) (%) −4.4± 7.5 −4.7± 9 0.62**
AIx_percentil_75 (1) (%) −6± 7 −9± 7 0.78**
AIx_percentil_75 (2) (%) −7± 8 −9± 9 0.87**
AIx_percentil_75 mean (1_2) (%) −6.5± 7.5 −9± 8 0.09**
AIx=Augmentation Index; AIx@75=Augmentation Index referred to 75 beats/minute; RHI=Reactive Hyperaemia Index
Values are means± standard deviation
*Mann–Whitney U-test
**Student’s t-test
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demonstrate those ﬁndings.8,49 This uncertainty about
long-term vascular function of Kawasaki disease
patients without history of coronary abnormalities is
also reﬂected on different guidelines approach on life-
long follow-up of these patients.50,51
Understanding the long-term vascular function in
Kawasaki disease patients is an important issue,
because its presence might represent ongoing
inﬂammatory reaction and can preclude increased
cardiovascular risk and the need for serial long-term
cardiac follow-up.14,16–22,34,48,52,53 In addition, con-
sidering that endothelium dysfunction is involved
in the atherosclerotic process, this raises questions about
similar pathological pathways.20–22,27,54
In this study, we found signiﬁcant late endothelial
dysfunction but absence of increased stiffness or
increased carotid intima-media thickness in the
majority of Kawasaki disease patients when
compared with matched controls. The endothelial-
dependent microvascular relaxation abnormality may
be a consequence of ongoing systemic inﬂammatory
process with sequelar damaged endothelium. The
ﬁnding of normal c-arterial intima-media thickness on
both carotid arteries and the absence of differences
between the two groups are consistent with the absence
of subclinical atherosclerotic changes, but we can
speculate that the observed histological changes in the
arterial walls of Kawasaki disease patients might take
longer time to evolve to atherosclerotic changes.33,34,48
Investigation of vascular function in Kawasaki
disease patients has recently been revived with
a number of similar studies published in the litera-
ture. Most of these studies were conducted in chil-
dren with Kawasaki disease having coronary artery
aneurysms. Noto et al20 found an increase in carotid
arterial intima-media thickness, in both children and
adults, late after the acute disease in patients with
coronary artery lesions. Cheung et al45 have specu-
lated that the increased carotid arterial intima-media
thickness in Kawasaki disease patients without cor-
onary involvement was associated with increased
systemic arterial stiffness; our study demonstrates the
opposite, as we did not ﬁnd a signiﬁcantly increased
augmentation index, a measure of arterial stiffness, or
Table 3. Right and left common carotid intima-media thickness (c-arterial intima-media thickness) measurements.
Kawasaki group (n= 43) Control group (n= 43) p Value
c-Arterial intima-media thickness left maximum 0.587± 0.100 0.575± 0.065 0.22**
c-Arterial intima-media thickness left mean 0.447± 0.088 0.443± 0.059 0.93*
c-Arterial intima-media thickness left SD 0.063± 0.022 0.062± 0.016 0.89*
c-Arterial intima-media thickness right maximum 0.598± 0.082 0.574± 0.074 0.34*
c-Arterial intima-media thickness right mean 0.441± 0.073 0.438± 0.058 0.89*
c-Arterial intima-media thickness right SD 0.062± 0.015 0.076± 0.084 0.37*




Box plots of the mean of two measurements of augmentation indices (AI and AI_Percentil_75) testing in Kawasaki disease patients and
controls.
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signiﬁcantly increased carotid intima-media thick-
ness, and we speculate this can represent different
genetic polymorphisms.
The consistency of endothelial dysfunction, in this
study, is in line with the one from Dhillon et al,11
which demonstrated abnormal ﬂow-mediated dilation
Figure 3.
Box plots of left and right maximum (a and b) and mean (c and d) carotid intima-media thickness (c-arterial intima-media thickness)
values in Kawasaki disease patients and controls.
Table 4. Logistic regression: calculated odds ratio value.
Odds ratio CI 95% p Value
RHI mean abnormal 16.5 5.7–47.8 <0.001
c-Arterial intima-media thickness_maximum_left (>0.6mm) 2.2 0.9–5.2 0.082
c-Arterial intima-media thickness_maximum_right (>0.6mm) 1.1 0.5–2.6 0.826
AIx mean 1.06 0.49–2.32 0.882
RCP 1.51 0.71–3.24 0.287
Triglycerides 1.24 0.58–2.65 0.582
Total cholesterol 1.73 0.80–3.74 0.162
HDL cholesterol 2.08 0.93–4.65 0.076
LDL cholesterol 1.50 0.69–3.24 0.305
AIx_percentil 75 1.18 0.53–2.62 0.686
AIx= augmentation index; CI= conﬁdence interval; RHI= reactive hyperaemia index; RCP=C-reactive protein
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of the brachial artery in 20 male subjects, who were
studied 5–17 years after the onset of Kawasaki
disease, irrespective of whether they had developed
aneurysms during the acute phase. Endothelial
dysfunction was also reported by Deng et al and Dalla
Pozza et al48 in some children with Kawasaki disease,
but without coronary artery aneurysms. Our study
adds evidence to these ﬁndings and suggests that
the occurrence of Kawasaki disease may have
lifelong consequences even when there is no coronary
artery involvement. This issue, however, is rather
controversial. Studies performed in Japanese subjects,
of identical characteristics, reported abnormal ﬂow-
mediated dilation only in patients who had devel-
oped coronary artery aneurysms during the acute
stage of Kawasaki.19,26 A Canadian study of 52
Kawasaki disease patients concluded that there was
no evidence of long-term endothelial cell dysfunction
late after Kawasaki disease onset.8 A recent American
study demonstrated that a mixed population of
Kawasaki disease patients with and without coronary
abnormalities had normal vascular health 1 year after
the Kawasaki disease episode.49 It is unclear whether
these conﬂicting results reﬂect methodological issues
or are best explained by genetic differences of the
studied populations.
Children with Kawasaki disease, with or without
coronary artery lesions, seem to have a more adverse
cardiovascular risk proﬁle, which requires lifelong
cardiac assessment and counselling, either sporadic or
serial. Whether this is a cause or a consequence of an
abnormal endothelial function has not yet been
assessed. We also failed to demonstrate premature or
subclinical atherosclerotic changes with the used
methodology. What is noteworthy is the fact that, in
our sample, almost 79% of Kawasaki disease patients
had endothelial dysfunction, when compared with
only 17% of the control subjects.
These ﬁndings suggest that children with
Kawasaki disease may have long-term sequelae, even
when there is no discernible coronary artery involve-
ment in the acute stage of the disease. Affected chil-
dren should therefore be kept on long-term follow-up
and counselled to reduce cardiovascular risk factors
such as sedentary lifestyle, overweight, high-lipid
and high-caloric meals, and alcohol or tobacco
use. Further research is needed to assess whether
known strategies to improve endothelial function
would bring potential beneﬁts to Kawasaki disease
patients.
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